Reports
Global Ovarian Cancer Diagnostics And Therapeutics Market: By Cancer Type: Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Others; By Modality: Diagnosis, Therapeutics; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis, Key Indicators for Demand; Competitive Landscape; 2024-2032
Global Ovarian Cancer Diagnostics and Therapeutics Market Outlook
The global ovarian cancer diagnostics and therapeutics market is projected to expand at a CAGR of 9.7% during the forecast period of 2024-2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growing geriatric population and increased awareness among people are driving the growth of the diagnostic and therapeutic industry for ovarian cancer globally.
Properties and Applications
Ovarian cancer is the fourth most prevalent cause of death from cancer in females worldwide, and the tenth most prevalent cancer among females in the U.S. Ovarian cancer incidences are high in females belonging to the age group of 54-65 years. Pelvic, bloating, and abdominal pain, eating trouble, and urinary symptoms are the main causes of ovarian cancer.
Ovarian diagnostics and therapeutics are used to detect, treat, and heal ovarian cancer. The global ovarian cancer diagnostics and therapeutics industry can be segmented into cancer type and modality.
The industry is divided based on its cancer type as epithelial ovarian tumours and ovarian germ cell tumours, among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry is broadly categorised based on its modality into:
- Diagnosis
- Biopsy
- Blood Tests
- Ultrasound
- PET
- CT Scan
- Others
- Therapeutics
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Hormonal Therapy
- Others
The EMR report looks into the regional markets of ovarian cancer diagnostics and therapeutics like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Market Analysis
The increasing incidences of ovarian cancer worldwide, the use of combination therapies for the treatment of ovarian cancer, and the rising geriatric population are some of the major factors accelerating the growth of the ovarian cancer diagnostics and therapeutics industry globally. The absence of accurate techniques to diagnose ovarian cancer and the lack of awareness regarding cancer detection and treatment in emerging and low-income economies are the major drawbacks that may affect the industry growth over the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
The report presents a detailed analysis of the following key players in the global ovarian cancer diagnostics and therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- AstraZeneca plc
- C.H. Boehringer Sohn AG & Ko. KG
- Bristol Myers Squibb Company
- Eli Lilly And Company
- F. Hoffmann-La Roche AG
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Cancer Type, Modality, Region |
| Breakup by Cancer Type | Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Others |
| Breakup by Modality | Diagnosis, Therapeutics |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | AstraZeneca plc, C.H. Boehringer Sohn AG & Ko. KG, Bristol Myers Squibb Company, Eli Lilly And Company, F. Hoffmann-La Roche AG, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Ovarian Cancer Diagnostics and Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Ovarian Cancer Diagnostics and Therapeutics Historical Market (2018-2023)
8.3 Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast (2024-2032)
8.4 Global Ovarian Cancer Diagnostics and Therapeutics Market by Cancer Type
8.4.1 Epithelial Ovarian Tumors
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Ovarian Germ Cell Tumors
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Others
8.5 Global Ovarian Cancer Diagnostics and Therapeutics Market by Modality
8.5.1 Diagnosis
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.1.3 Breakup by Type
8.5.1.3.1 Biopsy
8.5.1.3.1.1 Historical Trend (2018-2023)
8.5.1.3.1.2 Forecast Trend (2024-2032)
8.5.1.3.2 Blood Tests
8.5.1.3.2.1 Historical Trend (2018-2023)
8.5.1.3.2.2 Forecast Trend (2024-2032)
8.5.1.3.3 Ultrasound
8.5.1.3.3.1 Historical Trend (2018-2023)
8.5.1.3.3.2 Forecast Trend (2024-2032)
8.5.1.3.4 PET
8.5.1.3.4.1 Historical Trend (2018-2023)
8.5.1.3.4.2 Forecast Trend (2024-2032)
8.5.1.3.5 CT Scan
8.5.1.3.5.1 Historical Trend (2018-2023)
8.5.1.3.5.2 Forecast Trend (2024-2032)
8.5.1.3.6 Others
8.5.2 Therapeutics
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.2.3 Breakup by Type
8.5.2.3.1 Chemotherapy
8.5.2.3.1.1 Historical Trend (2018-2023)
8.5.2.3.1.2 Forecast Trend (2024-2032)
8.5.2.3.2 Radiation Therapy
8.5.2.3.2.1 Historical Trend (2018-2023)
8.5.2.3.2.2 Forecast Trend (2024-2032)
8.5.2.3.3 Immunotherapy
8.5.2.3.3.1 Historical Trend (2018-2023)
8.5.2.3.3.2 Forecast Trend (2024-2032)
8.5.2.3.4 Hormonal Therapy
8.5.2.3.4.1 Historical Trend (2018-2023)
8.5.2.3.4.2 Forecast Trend (2024-2032)
8.5.2.3.5 Others
8.6 Global Ovarian Cancer Diagnostics and Therapeutics Market by Region
8.6.1 North America
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Europe
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Asia Pacific
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Latin America
8.6.4.1 Historical Trend (2018-2023)
8.6.4.2 Forecast Trend (2024-2032)
8.6.5 Middle East and Africa
8.6.5.1 Historical Trend (2018-2023)
8.6.5.2 Forecast Trend (2024-2032)
9 North America Ovarian Cancer Diagnostics and Therapeutics Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Ovarian Cancer Diagnostics and Therapeutics Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.2 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Ovarian Cancer Diagnostics and Therapeutics Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 AstraZeneca plc
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 C.H. Boehringer Sohn AG & Ko. KG
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Bristol Myers Squibb Company
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Eli Lilly and Company
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 F. Hoffmann-La Roche AG
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Ovarian Cancer Diagnostics and Therapeutics Market: Key Industry Highlights, 2018 and 2032
2. Global Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Cancer Type (USD Million), 2018-2023
3. Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Cancer Type (USD Million), 2024-2032
4. Global Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Modality (USD Million), 2018-2023
5. Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Modality (USD Million), 2024-2032
6. Global Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Region (USD Million), 2018-2023
7. Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Region (USD Million), 2024-2032
8. North America Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
9. North America Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
10. Europe Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
11. Europe Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
13. Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Latin America Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
15. Latin America Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
17. Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Global Ovarian Cancer Diagnostics and Therapeutics Market Structure
Key Questions Answered in the Report
The global ovarian cancer diagnostics and therapeutics market is projected to grow at a CAGR of nearly 9.7% in the forecast period of 2024-2032.
The major drivers of the industry include the rising disposable incomes, increasing population, rising geriatric population, and the rising awareness about the cancer and its treatments among people.
The increased government funding and the surge in health care expenditure are expected to be the key trends guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.
The major cancer types in the industry include epithelial ovarian tumours and ovarian germ cell tumours, among others.
Diagnosis and therapeutics are the leading modality segments in the industry.
The leading players in the market are AstraZeneca plc, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly And Company, Hoffman-La Roche Ltd, GlaxoSmithKline Plc, and Johnson And Johnson, among others.
Analyst Review
The global ovarian cancer diagnostics and therapeutics market is being driven by the rising geriatric population. Aided by the rising incidences of cancer worldwide, the industry is expected to witness a healthy growth in the forecast period of 2024-2032, growing at a CAGR of 9.7%.
EMR’s meticulous research methodology delves deep into the industry, covering the macro and micro aspects of the industry. Based on cancer type, the market can be segmented into epithelial ovarian tumours and ovarian germ cell tumours, among others. On the basis of modality, the industry can be divided into diagnosis and therapeutics. The major regional markets of ovarian cancer diagnostics and therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above industry include AstraZeneca plc, C.H. Boehringer Sohn AG & Ko. KG, Bristol Myers Squibb Company, Eli Lilly And Company, F. Hoffmann-La Roche AG, Others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER